Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Raised by KPP Advisory Services LLC

KPP Advisory Services LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 33.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 3,768 shares of the medical research company's stock after purchasing an additional 945 shares during the period. KPP Advisory Services LLC's holdings in Thermo Fisher Scientific were worth $1,875,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of TMO. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock valued at $17,297,426,000 after buying an additional 196,864 shares in the last quarter. Capital World Investors lifted its holdings in Thermo Fisher Scientific by 1.1% in the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after acquiring an additional 104,343 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after purchasing an additional 197,442 shares during the last quarter. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $3,149,754,000. Finally, Northern Trust Corp boosted its position in Thermo Fisher Scientific by 13.2% during the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after purchasing an additional 455,004 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Argus cut their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Royal Bank Of Canada cut their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Scotiabank decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Citigroup cut their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $604.05.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $1.37 during mid-day trading on Thursday, hitting $412.02. The company's stock had a trading volume of 2,926,073 shares, compared to its average volume of 1,955,519. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The firm has a 50-day moving average price of $410.39 and a 200 day moving average price of $485.33. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The stock has a market capitalization of $155.53 billion, a price-to-earnings ratio of 24.17, a PEG ratio of 2.13 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm's revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.11 earnings per share. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.